Structural and Functional Insights into the HIV-1 Maturation Inhibitor Binding Pocket

PLoS Pathogens

Volumn 8, Issue 11, 2012, Pages

  Waki, Kayoko ^a   Durell, Stewart R ^b   Soheilian, Ferri ^c   Nagashima, Kunio ^c   Butler, Scott L ^d,e   Freed, Eric O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BEVIRIMAT; CAPSID PROTEIN; GAG PROTEIN; PF 46396; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRON MICROSCOPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MATURATION; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN POLYMORPHISM; RADIOIMMUNOPRECIPITATION; STRUCTURE ACTIVITY RELATION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS RESISTANCE; WESTERN BLOTTING;

ANTI-HIV AGENTS; BINDING SITES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; JURKAT CELLS; PROTEOLYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; TRITERPENES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84870782297     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002997     Document Type: Article

References (66)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337: 725-733.
3. Richman DD, (2001) HIV chemotherapy. Nature 410: 995-1001.
4. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, et al. (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-19.
5. Adamson CS, Freed EO, (2010) Novel approaches to inhibiting HIV-1 replication. Antiviral Res 85: 119-141.
6. Adamson CS, Salzwedel K, Freed EO, (2009) Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets 13: 895-908.
7. Freed EO, (1998) HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251: 1-15.
8. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203-217.
9. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, et al. (1989) Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5: 577-591.
10. Lee SK, Potempa M, Kolli M, Ozen A, Schiffer CA, et al. (2012) Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem 287: 13279-13290.
11. Tritch RJ, Cheng YE, Yin FH, Erickson-Viitanen S, (1991) Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol 65: 922-930.
12. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI, (1999) Assembly and analysis of conical models for the HIV-1 core. Science 283: 80-83.
13. Li S, Hill CP, Sundquist WI, Finch JT, (2000) Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407: 409-413.
14. Craven RC, Leure-duPree AE, Weldon RA Jr, Wills JW, (1995) Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol 69: 4213-4227.
15. Dorfman T, Bukovsky A, Ohagen A, Hoglund S, Gottlinger HG, (1994) Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol 68: 8180-8187.
16. McDermott J, Farrell L, Ross R, Barklis E, (1996) Structural analysis of human immunodeficiency virus type 1 Gag protein interactions, using cysteine-specific reagents. J Virol 70: 5106-5114.
17. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, et al. (1997) Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278: 849-853.
18. Bowzard JB, Wills JW, Craven RC, (2001) Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol 75: 6850-6856.
19. Cairns TM, Craven RC, (2001) Viral DNA synthesis defects in assembly-competent Rous sarcoma virus CA mutants. J Virol 75: 242-250.
20. Chang YF, Wang SM, Huang KJ, Wang CT, (2007) Mutations in capsid major homology region affect assembly and membrane affinity of HIV-1 Gag. J Mol Biol 370: 585-597.
21. Ebbets-Reed D, Scarlata S, Carter CA, (1996) The major homology region of the HIV-1 gag precursor influences membrane affinity. Biochemistry 35: 14268-14275.
22. Mammano F, Ohagen A, Hoglund S, Gottlinger HG, (1994) Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis. J Virol 68: 4927-4936.
23. Purdy JG, Flanagan JM, Ropson IJ, Rennoll-Bankert KE, Craven RC, (2008) Critical role of conserved hydrophobic residues within the major homology region in mature retroviral capsid assembly. J Virol 82: 5951-5961.
24. Strambio-de-Castillia C, Hunter E, (1992) Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol 66: 7021-7032.
25. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI, (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450.
26. Willems L, Kerkhofs P, Attenelle L, Burny A, Portetelle D, et al. (1997) The major homology region of bovine leukaemia virus p24gag is required for virus infectivity in vivo. J Gen Virol 78: 637-640.
27. Morellet N, Druillennec S, Lenoir C, Bouaziz S, Roques BP, (2005) Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci 14: 375-386.
28. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, et al. (2007) Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J 26: 2218-2226.
29. Accola MA, Hoglund S, Gottlinger HG, (1998) A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 72: 2072-2078.
30. Datta SA, Temeselew LG, Crist RM, Soheilian F, Kamata A, et al. (2011) On the role of the SP1 domain in HIV-1 particle assembly: a molecular switch? J Virol 85: 4111-4121.
31. Guo X, Roldan A, Hu J, Wainberg MA, Liang C, (2005) Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol 79: 1803-1812.
32. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H, (1995) The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol 69: 3407-3419.
33. Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, et al. (2006) Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 356: 217-224.
34. Liang C, Hu J, Russell RS, Roldan A, Kleiman L, et al. (2002) Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 Gag. J Virol 76: 11729-11737.
35. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, et al. (1994) Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57: 243-247.
36. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, et al. (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 45: 1225-1230.
37. Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, et al. (1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 39: 1016-1017.
38. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, et al. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 100: 13555-13560.
39. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, et al. (2004) Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 78: 922-929.
40. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, et al. (2006) In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 80: 10957-10971.
41. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO, (2009) Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 83: 4884-4894.
42. Zhou J, Huang L, Hachey DL, Chen CH, Aiken C, (2005) Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 280: 42149-42155.
43. Zhou J, Chen CH, Aiken C, (2006) Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3′,3′-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 80: 12095-12101.
44. Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, et al. (2006) 3-O-(3′,3′-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol 80: 5716-5722.
45. Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, et al. (2011) The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology 8: 101.
46. Martin DE, Salzwedel K, Allaway GP, (2008) Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother 19: 107-113.
47. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, et al. (2007) Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 51: 3574-3581.
48. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, et al. (2008) HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457). In: Proceedings of the XVII International HIV Drug Resistance Workshop; 10-14 June 2008; Sitges, Spain.
49. Seclen E, Gonzalez Mdel M, Corral A, de Mendoza C, Soriano V, et al. (2010) High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. AIDS 24: 467-469.
50. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, et al. (2009) HIV-1 Susceptibility to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag SP1. Antimicrob Agents Chemother 53: 2185-2188.
51. Adamson CS, Sakalian M, Salzwedel K, Freed EO, (2010) Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat. Retrovirology 7: 36.
52. Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, et al. (2011) A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother 55: 3324-3329.
53. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, et al. (2009) New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrob Agents Chemother 53: 5080-5087.
54. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC, (2010) HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol 85: 1420-1428.
55. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA, (1994) Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 68: 5311-5320.
56. Ono A, Demirov D, Freed EO, (2000) Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol 74: 5142-5150.
57. Ono A, Freed EO, (1999) Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol 73: 4136-4144.
58. Ono A, Orenstein JM, Freed EO, (2000) Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol 74: 2855-2866.
59. Ono A, Waheed AA, Joshi A, Freed EO, (2005) Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol 79: 14131-14140.
60. Taylor GM, Ma L, Vogt VM, Post CB, (2010) NMR relaxation studies of an RNA-binding segment of the rous sarcoma virus gag polyprotein in free and bound states: a model for autoinhibition of assembly. Biochemistry 49: 4006-4017.
61. Bharat TA, Davey NE, Ulbrich P, Riches JD, de Marco A, et al. (2012) Structure of the immature retroviral capsid at 8 A resolution by cryo-electron microscopy. Nature 487: 385-389.
62. Waheed AA, Ono A, Freed EO (2009) Methods for the study of HIV-1 assembly. In: HIV Protocols, second edition. p. 163-184.
63. Brissault B, Kichler A, Guis C, Leborgne C, Danos O, et al. (2003) Synthesis of linear polyethylenimine derivatives for DNA transfection. Bioconjug Chem 14: 581-587.
64. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, et al. (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291.
65. Freed EO, Martin MA, (1994) Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol 68: 2503-2512.
66. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, et al. (2009) X-ray structures of the hexameric building block of the HIV capsid. Cell 137: 1282-1292.